Ziv-aflibercept：与多种 VEGF-A 结合——更多是否意味着更好？
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
机构信息
Duke University Medical Center, Box 3182, 2301 Erwin Road, Durham, NC 27710, USA.
出版信息
Nat Rev Clin Oncol. 2013 Jan;10(1):10-1. doi: 10.1038/nrclinonc.2012.197. Epub 2012 Nov 13.
PMID:23149898
Abstract
The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. Thus, VEGF-directed agents might be useful throughout the continuum of care in mCRC, but biomarkers are needed to identify patients likely to benefit.
摘要
VELOUR 和 VITAL 研究最近表明，ziv-aflibercept 改善了转移性结直肠癌（mCRC）患者的总生存期，包括那些先前接受贝伐珠单抗治疗的患者，但在非小细胞肺癌中并未改善总生存期。因此，VEGF 靶向药物在 mCRC 的整个治疗过程中可能有用，但需要生物标志物来识别可能受益的患者。
Zotero 插件